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Abstract
Leukocyte telomere length has been proposed as a biomarker of cellular aging and atherosclerosis.
We sought to determine whether leukocyte telomere length is independently associated with
incident coronary heart disease (CHD) in the general population. Telomere length was measured
using a polymerase chain reaction method for participants enrolled in the 1995 Nova Scotia Health
Survey (n=1,917). The primary endpoint was first occurrence of fatal and non-fatal CHD events.
During a mean follow-up of 8.7 years, 164 fatal or non-fatal CHD events occurred. Compared to
participants in the longest tertile of telomere length, those in the middle and shortest tertiles had
increased incidence of CHD events (6.2, 11.2 and 12.2 per 1000 person-years, respectively). After
adjustment for demographics, traditional risk factors and inflammatory markers including hs-CRP,
IL-6, and sICAM-1, those in the middle tertile had significantly elevated risk for incident CHD
(hazard ratio [HR] 1.63, 95% CI 1.07–2.51, p=0.02) compared to the longest tertile, whereas the
risk for those in the shortest tertile was non-significantly elevated (HR 1.25, 95% CI 0.82–1.90,
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p=0.30). In conclusion, these findings do not support a linear association between leukocyte
telomere length and incident CHD risk in the general population.
Keywords
coronary heart disease; telomere; risk prediction
Introduction
Telomere length has been proposed as a novel biomarker for vascular aging and for CHD
onset.1 In 2003, Cawthon et al. reported that shorter leukocyte telomere length was
associated with an increased age-adjusted risk for cardiovascular mortality in a convenience
sample of 143 initially healthy individuals.2 Since that report, discordant findings have been
published with some studies showing weak or no association between leukocyte telomere
length and cardiovascular risk,3–7 and others suggesting a moderate to strong
association.1,8–12 These studies had notable limitations, such as restricting enrollment to the
very elderly leading to possible survival bias3,4,6,7, inclusion of participants with prior CHD
who are already at increased risk for subsequent events,3,6,8,12 and limited adjustment for
important confounders such as traditional CHD risk factors.3,4,7,8 Few studies have been
population-based, further limiting the generalizability of their findings. The extent to which
leukocyte telomere length constitutes a valid biomarker for incident CHD events in the
general population is thus unclear. To address this, we examined whether shorter leukocyte
telomere length was associated with the development of incident CHD events in participants
enrolled in the 1995 Nova Scotia Health Survey (NSHS95).
Patients and Methods
The NSHS95 is a population-based survey implemented by Heart Health Nova Scotia and
the Nova Scotia Department of Health. Study participants consisted of non-institutionalized,
non-pregnant Nova Scotians, age 18 years or older, and listed in the registry of the national
health insurance plan. Of 4,500 targeted participants, a total of 3,227 provided informed
consent and were enrolled. The overall recruitment percentage (72%) is comparable to other
large health surveys, and weights applied from propensity score analyses revealed no
meaningful response bias.13 The current study was approved by the institutional review
boards of Dalhousie University, Halifax, Nova Scotia, and Columbia University Medical
Center, New York, NY.
For this analysis, we excluded 1,310 participants as follows (Figure 1): 244 participants with
prior history of CHD, as determined by claims records for the 5 years preceding the baseline
survey using International Classification of Diseases, Ninth Revision (ICD-9) codes 410.x
through 414.x (myocardial infarction, acute or chronic ischemic heart disease, angina); 295
participants who did not provide permission for ascertainment of cardiac outcomes; 757
participants who did not have blood samples for telomere length assay; and 14 participants
who granted permission but did not have available outcome data. The final cohort thus
consisted of 1,917 participants. Compared to the 1,917 participants who had a blood sample
for telomere length assessment and had available outcome data, there was no significant
difference in age (p=0.20), sex (p=0.52), and Framingham risk score (p=0.92) as defined
below for participants who did not have telomere length assessment and/or outcome data
(n=771).
From March through November of 1995, a group of trained nurses contacted eligible
individuals and interviewed those who agreed to participate. Those who were interviewed
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also visited a health care clinic approximately 1 week after. At the clinic visit, height and
weight were measured, and a comprehensive set of cardiovascular risk factors and full
medical history were assessed. A fasting blood sample was obtained and processed for
plasma and buffy coat samples. Medication use was recorded during a home visit.
DNA was extracted from frozen buffy coat samples. Average telomere length was
determined by a real-time polymerase chain reaction (PCR) method modified from that of
Cawthon et al.2,14,15 Real-time PCR was performed using a CFX384 thermocycler (Biorad,
Richmond, CA). The assay method was optimized for use of both telomere (T) and single
copy gene (S) amplifications on the same 384-well plate, with reference standard DNA
samples on each plate. Test DNA samples each underwent two triplicate PCR reactions,
with use of calibrator samples for correction of inter-plate variability. Amplification primers
for telomeres included Tfor: 5’-
CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT-3’ and Trev: 5’-
GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT-3’, and for single copy
gene (beta-globin) Sfor 5’-GCTTCTGACACAACTGTGTTCACTAGC-3’ and Srev 5’-
CACCAACTTCATCCACGTTCACC-3’. Thermocycling parameters were 95°C × 10min
activation, followed by 34 cycles of 95°C × 15sec, and 55°C × 120sec. The assay coefficient
of variance was 5–8%. Since the T/S ratio depends on particular DNA standards used, T/S
ratios were converted to telomere base pairs (bp) using a formula (bp = (1,585 * T/S ratio) +
3,582) derived from co-analysis of 19 selected DNA samples (correlation coefficient r =
0.90)14 with both PCR and terminal restriction fragment methods (non-radioactive
TeloTAGGG Telomere Length, Roche Diagnostics, Mannheim, Germany). Because
telomere base pairs are calculated from T/S ratio in a linear fashion, tertiles of telomere
length and all resulting statistics were identical between the two measurements. In this
analysis, we present telomere length results in base pairs, although caution should be used in
comparing absolute telomere length measurements between studies, because of differing
methodologies.
Participants’ age and sex were recorded from the provincial health insurance registry and
verified by the interviewer. Body mass index (BMI) was calculated as weight in kilograms
divided by height in meters squared. Systolic blood pressure and diastolic blood pressure
were measured using manual sphygmomanometers. Total cholesterol, high-density
lipoprotein (HDL) cholesterol, and triglyceride levels were assayed from plasma samples,
and low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald
formula.16 History of diabetes was ascertained by self-report. Those who reported smoking
currently or in the past year were considered smokers. Framingham risk score was
calculated using age, sex, total and HDL cholesterol levels, systolic blood pressure, and
history of diabetes and cigarette smoking.17 Lipid lowering medication use was defined as
the use of statins, fibrates, bile acid sequestrants, or nicotinic acid. Physical activity was
assessed using the Paffenbarger Scale.18 Three inflammatory markers, high sensitivity C-
reactive protein (hs-CRP), interleukin-6 (IL-6), and soluble intercellular adhesion
molecule-1 (sICAM-1), were measured from plasma samples. hs-CRP was measured using a
latex-enhanced immunonephelometry assay (Cardiophase BN II; Dade Behring, New Castle,
Delaware). IL-6 was assessed using a high-sensitivity enzyme-linked immunosorbent assay
kit (Quantikine HS IL-6; R&D Systems, Minneapolis, Minnesota), and sICAM-1 using a
commercially available enzyme-linked immunosorbent assay kit (R&D Systems,
Minneapolis, Minnesota). Additional details of study procedures and biomarkers
assessments have been published previously.19
The primary outcome measure was time-to-first occurrence of fatal or nonfatal CHD event,
as determined from hospital discharge codes (ICD-9 codes 410 through 414 and ICD-10
codes I21–I25) and cause of death listed on death certificates. In Canada, the available
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medical care utilization data included nearly all hospital care delivered to the survey
participants. The ICD codes were gathered from the provincial hospital discharge database
for a 10-year period following the date of the baseline assessment. For non-fatal CHD
events, personnel who performed abstraction were trained and certified, and met regularly
with a data quality committee from the Department of Health (Nova Scotia) to ensure
accuracy and to adjudicate data entry irregularities. In Canada, Statistics Canada keeps vital
statistics at the national level, capturing all deaths including those that occurred at home.
Causes of death were coded using ICD codes through a nationally consistent process. For
secondary analyses, we also examined the combined endpoint of fatal or non-fatal CHD
events or all-cause mortality, as well as all-cause mortality only, non-fatal CHD events only,
and fatal CHD events only.
For the primary analysis, based on prior studies, the exposure variable was specified a priori
as tertiles of telomere length.1,6,9,12 Baseline demographics and cardiovascular risk factors
as well as levels of inflammatory markers were calculated by tertiles of telomere length.
Testing for trend of association of baseline characteristics with increasing tertiles of
telomere length was performed using Goodman and Kruskal’s gamma statistic for
categorical variables, and chi-square statistic from linear regression for continuous variables.
The association between log-transformed telomere length (due to skewed distribution) and
age was assessed using linear regression. To determine the relationship between telomere
length and incident CHD events, three Cox proportional hazards regression models were
constructed to estimate the hazard ratios (HR) of having telomere length in the middle and
shortest tertiles as compared to the longest tertile (reference group). Model 1 adjusted only
for age and sex; model 2 adjusted for variables in model 1 plus BMI, Framingham risk score
as a continuous variable, use of lipid lowering medications, and physical activity; model 3
adjusted for variables in model 2, plus inflammatory biomarker levels including log-
transformed hs-CRP and log-transformed IL-6 (both due to skewed distribution), and
sICAM-1. Next, secondary end points (the composite of fatal and non-fatal CHD events and
all-cause mortality, all-cause mortality only, non-fatal CHD events only, and fatal CHD
events only) were used as outcome measures in fully-adjusted models that included all
covariates in Model 3. Because telomere biology may differ between men and women,20
sensitivity analyses were performed using tertiles stratified by sex. For each model,
assumptions of proportional hazards were verified with a formal significance test based on
Schoenfeld residuals.21 A test of non-linearity was conducted by considering tertiles of
telomere length as both linear and quadratic terms while adjusting for all other covariates in
Model 3. All statistical analyses were performed using STATA version 10.0 (StataCorp,
College Station, Texas) and SPSS version 18.0 (IBM, Chicago, Illinois).
Results
For the 1,917 participants included for this analysis, the mean (SD) age was 46.6 (18.4)
years, and 51% were women. Tests for linear trends demonstrated that participants in shorter
tertiles of telomere length were older, less likely to be smokers, had higher systolic and
diastolic blood pressures, higher Framingham risk score and risk categories, higher levels of
LDL, and higher levels of hs-CRP (Table 1). Log telomere length was inversely correlated
with age (r=−0.22 and R2=0.049, p<0.001). For each decade increase in age, a 1.3% (95%
CI, 1.0% to 1.5%) decrease in telomere length was observed (p<0.001).
During a mean follow-up period of 8.7 years, 164 fatal or non-fatal CHD events occurred.
The incidence of fatal and non-fatal CHD events was higher for participants in the middle
and shortest tertiles, compared to those in the longest tertile (Table 2 and Figure 2). After
adjusting for age and sex, participants in the middle tertile continued to have a significantly
increased risk of incident CHD (HR 1.63, 95% CI 1.08–2.47; p=0.02), while participants in
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the shortest tertile had a non-significantly increased risk (HR 1.22, 95% CI 0.81–1.83;
p=0.35) (Table 2, Model 1). These relationships were similar after adjustment for BMI,
Framingham risk score, baseline lipid-lowering medication use including statins, and
physical activity (Table 2, Model 2) and further adjustment for inflammatory biomarkers
including hs-CRP, IL-6, and sICAM-1 (Table 2, Model 3). Non-linearity of the association
of tertiles of telomere length to incident CHD events was demonstrated using a model that
included tertiles of telomere length as both linear and quadratic terms (p=0.028) in addition
to all other covariates in Model 3.
Compared to participants in the longest tertile, participants in the middle and shortest tertiles
of telomere length had increased number for all secondary endpoints (Table 3). However,
after adjustment for demographic factors, traditional risk factors and inflammatory markers,
the HRs for secondary endpoints were non-significant, with the exception of non-fatal CHD
events, for which the risk was significantly increased for participants in the middle tertile of
telomere length compared to those in the longest tertile. The HRs for participants in the
middle tertile were non-significantly higher than those for the shortest tertile for all other
end points.
Sensitivity analyses were performed using tertiles of telomere length stratified by sex. After
full adjustment, the pattern of results differed by sex, although associations for each tertile
were not statistically significant. For men, the adjusted HRs for incident CHD events were
1.41 (95% CI 0.82–2.42; p=0.82) for those in the middle tertile of telomere length and 0.94
(95% CI 0.55–1.61; p=0.61) for those in the shortest tertile. However, for women, the
adjusted HRs for incident CHD events were similar for both those in the middle (HR 1.72,
95% CI 0.85–3.48; p=0.13) and those in the shortest tertiles (HR 1.72, 95% CI 0.89–3.36;
p=0.11), compared to those in the longest tertile.
Discussion
There are several findings from our analysis of the relationship between telomere length and
risk of incident CHD in this population-based cohort. First, in an unadjusted model, shorter
telomere length was associated with an increased risk of fatal and non-fatal incident CHD
events. However, after adjustment for demographics, traditional cardiovascular risk factors
and inflammatory markers, there was a non-linear association of tertiles of telomere length
with incident CHD events, with participants in the middle tertile of telomere length having
significantly increased risk of incident CHD compared with those in the longest tertile,
while those in the shortest tertile did not. Lastly, the pattern of increased CHD risk may
differ by sex. In contrast to men, elevated CHD risk was observed for both those in the
middle and shortest tertiles of telomere length in women, although these findings did not
reach statistical significance.
Previous reports on the relationship between telomere length and cardiac outcomes have
produced inconsistent results. Many of the studies that failed to demonstrate a relationship
between telomere length and cardiovascular risk exclusively enrolled very elderly
participants, with mean ages ranging from 75 to 90 years.3,6 Given that telomere length
decreases with age, restricting enrollment to the very elderly may exclude individuals with
shorter telomere lengths who have already died, resulting in a survivor bias. In contrast,
previous studies that included participants with a broader age range as in our study generally
found that shorter telomere length being associated with increased cardiovascular risk,8,12
though results from a very large population-based study (n=19,838) showed that the strength
of this association was modest.22
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It is unclear why the middle tertile of telomere length had a stronger association with CHD
events than the shortest tertile in our sample. One explanation is that competing risks from
non-cardiovascular deaths may have played a role. Previous studies have shown that
individuals with the shortest telomere lengths are at increased risk for incident cancers and
also infectious deaths,2,23,24 suggesting that the type of disease outcomes may vary by the
severity of telomere shortening. It is thus possible that participants in the shortest tertile of
telomere length in our study were affected by non-CHD outcomes. Furthermore, Epel et al.
hypothesized that competing risks such as cancer or infectious causes of death may operate
more strongly in men,10 suggesting a biological reason for the potential sex differences we
observed. Future studies are needed explore differential predictive values of shorter telomere
lengths in men and women, as well as the relationship between telomere length and different
causes of death.
Along with the current state of knowledge, our results suggest that telomere length may not
have the “ideal” characteristics of a disease-specific biomarker for predicting incident CHD
events.25,26 Telomere length may have a complex, non-linear relationship with incident
CHD events that is affected by competing risks from other disease processes. In addition,
the relatively small decrement in telomere length with increasing age implies that small
measurement variation in assays may have a disproportionate effect in models that use
telomere length for risk prediction.27 Thus, from these results, telomere length cannot be
used as a biomarker that has specific “cut-points” for determination of CHD risk. Additional
studies would be required to demonstrate the incremental value of telomere length
assessment over traditional risk factors.
Our study has several strengths. We used a relatively large, provincially-representative,
population-based sample to investigate the relationship between telomere length and the risk
of incident CHD. In addition to traditional risk factors, we also assessed inflammatory
biomarkers as covariates. We were also able to achieve complete capture of CHD outcomes
through centralized databases. There are also several limitations. Although we measured
leukocyte telomere length, it is possible that telomere length of specific leukocyte
subpopulations or of cardiac or vascular cells might correlate better with cardiac risk. In
addition, a single measurement of telomere length cannot indicate whether longitudinal
changes in telomere length may better predict CHD risk.10,28 Finally, the number of CHD
events in this sample was relatively small, and we did not have data on non-CHD disease
processes. As such, we could not evaluate the effect of competing risks from non-CHD
outcomes.
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Figure 1. Participants available for analysis of telomere length in the 1995 Nova Scotia Health
Survey
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Figure 2. Cumulative incidence of fatal and non-fatal CHD events, by tertiles of telomere length
(in kilo-bases)
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Table 1
Baseline characteristics of 1,917 participants by tertiles of telomere length (in kilo-bases)
Tertiles of telomere length
Telomere length (kilo-bases) 5.5 to 8.2
(n = 639)





Telomere-to-single copy gene ratio 1.20 to 2.90 0.92 to <1.20 0.30 to <0.92
Age (years) 41.7 (18.0) 46.1 (17.8) 51.8 (18.1) < 0.001
Female 330 (51.6%) 340 (53.2%) 308 (48.2%) 0.11
Smokers 193 (30.2%) 160 (25.0%) 158 (24.7%) 0.01
Body mass index (kg/m2) 26.6 (5.4) 27.2 (6.1) 27.1 (5.0) 0.10
Diabetes mellitus 21 (3.3%) 26 (4.1%) 23 (3.6%) 0.38
Systolic blood pressure (mm Hg) 123.3 (16.1) 124.6 (17.7) 127.1 (17.5) < 0.001
Diastolic blood pressure (mm Hg) 76.0 (9.9) 77.0 (9.5) 77.5 (9.2) 0.01
Low-density lipoproteins (mmol/L) 3.1 (0.9) 3.2 (0.9) 3.4 (0.9) < 0.001
     (mg/dL) 119.9 (34.8) 123.7 (34.8) 131.5 (34.8)
High-density lipoproteins (mmol/L) 1.3 (0.3) 1.3 (0.3) 1.3 (0.4) 0.42
     (mg/dL) 50.3 (11.6) 50.3 (11.6) 50.3 (15.5)
Use of lipid-lowering medications 21 (3.3) 18 (2.8) 16 (2.5) 0.20
Framingham risk score −0.8 (9.9) 1.5 (8.9) 3.7 (8.0) < 0.001
Framingham risk category < 0.001
      0 – 10% 491 (76.8%) 466 (72.9%) 394 (61.7%)
      10 – 20% 75 (11.7%) 111 (17.4%) 139 (21.8%)
      > 20% 73 (11.4%) 62 (9.7%) 106 (16.6%)
hs-CRP level, median (IQR) (mg/L) 1.4 (0.5 – 3.4) 1.6 (0.5 – 3.6) 1.9 (0.7 – 4.4) 0.005
IL-6 level, median (IQR) (pg/mL) 1.1 (0.7 – 1.9) 1.1 (0.7 – 1.9) 1.2 (0.8 – 2.2) 0.38
sICAM-1 level (ng/mL) 635.5 (341.7) 543.2 (328.2) 528.4 (313.9) < 0.001
Values are mean (SD) or n (%) except where noted otherwise. P-values for increasing tertiles of telomere length was performed using Goodman
and Kruskal’s gamma statistic for categorical variables, and chi-square statistic derived from linear regression for continuous variables. Trend
testing for hs-CRP and IL-6 levels was performed after log-transform due to for skew.
Abbreviations. CRP, C-reactive protein; IL-6, interleukin-6; sICAM-1, soluble intracellular adhesion molecule-1
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Table 2
Incident rates and hazard ratios for fatal and non-fatal coronary heart disease events by tertiles of telomere
length (in kilo-bases)







Telomere length (kilo-bases) 5.5 to 8.2 5.0 to < 5.5 4.1 to <5.0
Number of events 35 62 67
Incidence per 1,000 person-years 6.2 11.2 12.2
Hazard ratios (95% CI)
Unadjusted 1.00 (Reference) 1.81 (1.20–2.75) 1.97 (1.31–2.96)
      Model 1* 1.00 (Reference) 1.63 (1.08–2.47) 1.22 (0.81–1.83)
      Model 2† 1.00 (Reference) 1.64 (1.07–2.50) 1.30 (0.86–1.97)
      Model 3‡ 1.00 (Reference) 1.63 (1.07–2.51) 1.25 (0.82–1.90)
*
Model 1 includes adjustment for age and sex.
†
Model 2 includes adjustment for covariates in Model 1 plus body mass index, Framingham risk score, use of lipid-lowering medications, and
physical activity.
‡
Model 3 includes adjustment for covariates in Model 2 plus ln CRP, ln IL6, and sICAM-1.
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Table 3
Hazard ratio for clinical events by tertiles of telomere length (in kilo-bases) and event type*







Telomere length (kilo-bases) 5.5 to 8.2 5.0 to < 5.5 4.1 to <5.0
CHD event or all-cause mortality
      Number of events 70 96 122
      Hazard ratio (95% CI) 1.00 (Reference) 1.30 (0.94–1.80) 1.09 (0.81–1.48)
All-cause mortality only
      Number of events 46 52 83
      Hazard ratio (95% CI) 1.00 (Reference) 1.11 (0.73–1.69) 1.12 (0.77–1.62)
Non-fatal CHD events only
      Number of events 34 58 61
      Hazard ratio (95% CI) 1.00 (Reference) 1.56 (1.00–2.41) 1.17 (0.76–1.80)
Fatal CHD events only
      Number of events 4 8 11
      Hazard ratio (95% CI) 1.00 (Reference) 2.05 (0.61–6.92) 1.79 (0.56–5.72)
*
Hazard ratios are adjusted for age, sex, body mass index, Framingham risk score, use of lipid-lowering medications, physical activity, ln CRP, ln
IL6, and sICAM-1.
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